Comparison of efficacy and tolerability of gemcitabine and gemcitabine plus nab-paclitaxel in 2nd line therapy for pancreatic cancer. Experience of one center
Open Access
- 20 June 2026
- journal article
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 99-106
Abstract
Background. First-line therapy for advanced pancreatic cancer often involves combination regimens, including gemcitabine plus nab-paclitaxel (GEM-NAB), whereas the optimal treatment strategy in the second-line setting remains a subject of debate. Aim. To compare efficacy and tolerability of gemcitabine (GEM) monotherapy and GEM-NAB combination as second-line treatment for pancreatic cancer. Materials and methods. This retrospective single-center study was conducted in patients with pancreatic adenocarcinoma receiving second-line chemotherapy with one of two regimens: GEM monotherapy or the GEM-NAB combination. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and safety. Results. A total of 118 patients were included: 57 received GEM and 61 received GEM-NAB. The groups were comparable in baseline clinical and demographic characteristics. Median follow-up was 9 months. Median OS was 5.9 months (95 % confidence interval (CI) 3.8–8.0) in the GEM group and 6.4 months (95 % CI 4.5–8.3) in the GEM-NAB group (p = 0.772). Median progression-free survival was 3.3 months (95 % CI 2.8–3.8) and 4.7 months (95 % CI 3.6–5.8), respectively (p = 0.079). Objective response rate was 15.8 % and 28.6 %, respectively (p = 0.127). The incidence of grade III–IV adverse events was comparable between the groups. In multivariate analysis, ECOG status ≥ 2, liver metastases, and decreased hemoglobin level were identified as independent predictors of poor survival. Conclusion. Gemcitabine plus nab-paclitaxel combination as 2nd line therapy did not demonstrate statistically significant improvement in overall survival compared with gemcitabine monotherapy and showed a comparable safety profile.Keywords
This publication has 11 references indexed in Scilit:
- Cancer statistics, 2025CA: A Cancer Journal for Clinicians, 2025
- Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 2021
- Iatrogenic perforation and endoscopic closure: It's time to replace surgery?Clinics and Research in Hepatology and Gastroenterology, 2020
- Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysisTherapeutic Advances in Medical Oncology, 2020
- Prognostic factors in advanced pancreatic cancer patients receiving second-line chemotherapy: a single institution experienceTranslational Cancer Research, 2018
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBritish Journal of Cancer, 2009
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997